To date, the company has developed two platforms: the Carragelose platform and the Marinosolv technology platform.

The Carragelose platform is already used in six different products to treat viral infections of the respiratory tract, which are sold globally via the company’s partners.

Meanwhile, the Marinosolv technology platform enhances the efficacy of hardly soluble compounds. The technology has the potential to sustainably change a number of therapies for allergies and autoimmune diseases.

Marinomed's flagship product, Budesolv, is about to enter its pivotal Phase III approval study.